Skip to main content

Powerlifting Athlete Suspended for Presence of Stimulants

CCES Logo

English

Press Release

8 November 2017

The Canadian Centre for Ethics in Sport (CCES) announced today that Niko Somos, a powerlifting athlete, received a two-year sanction for an anti-doping rule violation. The athlete’s urine sample, collected during in-competition doping control on July 9, 2017, revealed the presence of oxilofrine and 1,3-dimethylbutylamine, prohibited stimulants.  

Oxilofrine and 1,3-dimethylbutylamine are classified as “specified substances” on the World Anti-Doping Agency (WADA) Prohibited List, banned in-competition. Under the rules of the Canadian Anti-Doping Program (CADP), the period of ineligibility for a first violation for the presence of a “specified substance” is two years, unless an athlete can meet the conditions for eliminating or reducing the period of ineligibility.

In response to the CCES’ notification of the adverse analytical finding, Mr. Somos admitted the violation in a timely fashion (in accordance with CADP Rule 10.11.2), waived his right to a hearing and accepted a sanction of two years ineligibility from sport, terminating on July 8, 2019. The athlete, who resides in Edmonton, Alberta, is ineligible to participate in any capacity with any sport signatory to the CADP, including training with teammates.

In compliance with rule 7.10 of the CADP, a copy of the CCES’ file outcome summary can be found at www.cces.ca/sanctionreg.

The CCES is an independent, national, not-for profit organization with a responsibility to administer the CADP. Under the CADP rules, the CCES announces publicly every anti-doping rule violation. We recognize that true sport can make a great difference for individuals, communities and our country. We are committed to working collaboratively to activate a values-based and principle-driven sport system; protecting the integrity of sport from the negative forces of doping and other unethical threats; and advocating for sport that is fair, safe and open to everyone.